Designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.
Aims to enable the generation of high quality material and data in under five months to move rapidly towards IND approval and GMP clinical manufacturing.
Early phase drug development is often defined by speed, but planning is essential to avoid added costs and delays in the later stages of a molecule’s journey.
Mat Minardi and John Mykytiuk, Sterling Pharma Solutions10.03.22
Explora BioLabs operates 15 preclinical vivarium facilities, offering rental space in the Southern California, San Francisco, and Boston-Cambridge biohubs.
Removing API supply as a criterion in the “Go/No-Go” decision tree and enhancing the opportunity to successfully navigate the pharmaceutical “Valley of Death.”
Thomas Daggs and Angelo Consalvo, Enteris BioPharma 06.07.21